Press Releases

LOS ANGELES, June 1, 2024 /PRNewswire/ -- Vincent Todd is pleased to announce the introduction of generative agriculture firm Todd Agriscience. Capitalizing on the Founder's collective experience partnering in and building small scale organic and biodynamic farms, along with Todd's global reach and unrivaled social influence, the firm will guide management strategies in growth-oriented, market-leading organic and biodynamic farms. Todd Agriscience's primary focus is... (continue reading...)

• Total sales up 12% in May; YTD total sales increase 2%
• Best May for IONIQ 5, IONIQ 6, Tucson HEV, Santa Fe HEV, Palisade and Santa Cruz
• Hyundai May retail sales up 9% YOY; Volume led by Palisade, IONIQ 5 and Santa Fe HEV
• May EV sales up 42% YOY

FOUNTAIN VALLEY, Calif., June 1, 2024 /PRNewswire/ -- Hyundai Motor America reported total May sales of 78,485 units, a 12% increase compared with May 2023. Hyundai set total sales records in May for IONIQ 5 (+82%), IONIQ 6... (continue reading...)

An Innovative Line of Professional Cosmeceutical Formulas Designed To Help People "Rewind Time" on their Skin

BEVERLY HILLS, Calif., June 1, 2024 /PRNewswire/ -- Beverly Hills MD®, the cutting-edge skincare line created by renowned plastic surgeons Dr. John Layke and Dr. Payman Danielpour, is celebrating its 10th anniversary. Founded in 2014 by Dr. Layke and Dr. Danielpour, who co-founded the Beverly Hills Plastic Surgery Group, Beverly Hills MD emerged from their... (continue reading...)

Collaboration advances Cancer Moonshot call to empower patients, reduce duplication

CHICAGO, June 1, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the American Society of Clinical Oncology (ASCO) today announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership between ASCO, the leading organization for cancer care providers, and ACS, the leading patient education, support, and... (continue reading...)

Ankyra Therapeutics will provide an update on the status of the ANK-101 Phase 1 ANCHOR clinical trial at ASCO 2024 and has received approval by FDA and Health Canada to amend the Phase I study to include patients with solid tumors in visceral organs

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced today that it is... (continue reading...)